Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study
Michiel Zietse(Erasmus MC), Frederick W. Thielen(University Medical Center Freiburg), Agnes Jager(Erasmus MC Cancer Institute), Ron H.J. Mathijssen(Erasmus MC), Leontine E A M M Spierings(Alrijne Ziekenhuis), Jun Hu(Erasmus MC), Birgit C. P. Koch(University Medical Center Groningen), Esther R van Staveren(Alrijne Ziekenhuis), Roelof W. F. van Leeuwen(Erasmus MC)
Cited by 3
Related Papers
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
|PubMed|2001|752
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345